- Home
- LSF vs ANL Comparison
LSF vs ANL Comparison
Compare LSF & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSF | ANL |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 350.9M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LSF | ANL |
|---|---|---|
| Price | $2.69 | $8.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $16.00 |
| AVG Volume (30 Days) | 66.9K | ★ 459.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,295,137.00 | N/A |
| Revenue This Year | $15.87 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.50 | N/A |
| 52 Week Low | $1.98 | $0.88 |
| 52 Week High | $7.94 | $12.09 |
Technical Indicators
Market Signals| Indicator | LSF | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 52.82 |
| Support Level | $2.46 | $1.36 |
| Resistance Level | $2.76 | $12.09 |
| Average True Range (ATR) | 0.22 | 0.82 |
| MACD | -0.02 | -0.47 |
| Stochastic Oscillator | 34.68 | 36.73 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.